ID   FETUA_RAT               Reviewed;         352 AA.
AC   P24090; Q5BKD2;
DT   01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 2.
DT   24-JUL-2024, entry version 164.
DE   RecName: Full=Alpha-2-HS-glycoprotein;
DE   AltName: Full=59 kDa bone sialic acid-containing protein;
DE            Short=BSP;
DE   AltName: Full=Fetuin-A;
DE   AltName: Full=Glycoprotein PP63;
DE   Flags: Precursor;
GN   Name=Ahsg; Synonyms=Fetua;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1371750; DOI=10.1111/j.1432-1033.1992.tb16663.x;
RA   Rauth G., Poeschke O., Fink E., Eulitz M., Tippmer S., Kellerer M.,
RA   Haering H., Nawratil P., Haasemann M., Jahnen-Dechent W.,
RA   Mueller-Esterl W.;
RT   "The nucleotide and partial amino acid sequences of rat fetuin. Identity
RT   with the natural tyrosine kinase inhibitor of the rat insulin receptor.";
RL   Eur. J. Biochem. 204:523-529(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=2766355; DOI=10.1016/0092-8674(89)90098-6;
RA   Auberger P., Falquerho L., Contreres J.O., Pages G., le Cam G., Rossi B.,
RA   le Cam A.;
RT   "Characterization of a natural inhibitor of the insulin receptor tyrosine
RT   kinase: cDNA cloning, purification, and anti-mitogenic activity.";
RL   Cell 58:631-640(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND SEQUENCE REVISION.
RX   PubMed=1849862; DOI=10.1016/0378-1119(91)90175-b;
RA   Falquerho L., Patey G., Paqureau L., Rossi V., Lahuna O., Szpirer J.,
RA   Szpirer C., Levan G., le Cam A.;
RT   "Primary structure of the rat gene encoding an inhibitor of the insulin
RT   receptor tyrosine kinase.";
RL   Gene 98:209-216(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7681247; DOI=10.1002/jbmr.5650080314;
RA   Ohnishi T., Nakamura O., Ozawa M., Arakaki N., Muramatsu T., Daikuhara Y.;
RT   "Molecular cloning and sequence analysis of cDNA for a 59 kD bone
RT   sialoprotein of the rat: demonstration that it is a counterpart of human
RT   alpha 2-HS glycoprotein and bovine fetuin.";
RL   J. Bone Miner. Res. 8:367-377(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Spleen;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 19-35; 51-64; 165-180; 231-247 AND 327-348.
RC   TISSUE=Mandible;
RX   PubMed=1860865; DOI=10.1016/s0021-9258(18)98733-8;
RA   Ohnishi T., Arakaki N., Nakamura O., Hirono S., Daikuhara Y.;
RT   "Purification, characterization, and studies on biosynthesis of a 59-kDa
RT   bone sialic acid-containing protein (BSP) from rat mandible using a
RT   monoclonal antibody. Evidence that 59-kDa BSP may be the rat counterpart of
RT   human alpha 2-HS glycoprotein and is synthesized by both hepatocytes and
RT   osteoblasts.";
RL   J. Biol. Chem. 266:14636-14645(1991).
RN   [7]
RP   IDENTITY OF PP63 WITH FETUIN.
RX   PubMed=1707273; DOI=10.1042/bj2740899;
RA   Haasemann M., Nawratil P., Mueller-Esterl W.;
RT   "Rat tyrosine kinase inhibitor shows sequence similarity to human alpha 2-
RT   HS glycoprotein and bovine fetuin.";
RL   Biochem. J. 274:899-902(1991).
RN   [8]
RP   IDENTITY OF PP63 WITH FETUIN.
RX   PubMed=1370655; DOI=10.1016/0092-8674(92)90200-v;
RA   Brown W.M., Christie D.L., Dziegielewska K.M., Saunders N.R., Yang F.;
RT   "The rat protein encoded by clone pp63 is a fetuin/alpha 2-HS glycoprotein-
RT   like molecule, but is it the tyrosine kinase inhibitor pp63?";
RL   Cell 68:7-8(1992).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-138, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=16641100; DOI=10.1073/pnas.0600895103;
RA   Hoffert J.D., Pisitkun T., Wang G., Shen R.-F., Knepper M.A.;
RT   "Quantitative phosphoproteomics of vasopressin-sensitive renal cells:
RT   regulation of aquaporin-2 phosphorylation at two sites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:7159-7164(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-138; SER-309; SER-313;
RP   SER-316 AND SER-318, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Could inhibit both insulin-receptor tyrosine kinase activity
CC       and insulin-stimulated receptor autophosphorylation and, concomitantly,
CC       antagonize the mitogenic effect of the hormone in cultured rat hepatoma
CC       cells.
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- TISSUE SPECIFICITY: Synthesized in liver and secreted by the
CC       hepatocytes in the blood.
CC   -!- PTM: Undergoes complex post-translational modification involving N-
CC       glycosylation, and addition of fucose and sialic acid residues.
CC       Phosphorylation occurs at a serine residue.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000250|UniProtKB:P02765}.
CC   -!- SIMILARITY: Belongs to the fetuin family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00861}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X63446; CAA45042.1; -; mRNA.
DR   EMBL; M29758; AAA75502.1; -; mRNA.
DR   EMBL; D10261; BAA01101.1; -; mRNA.
DR   EMBL; BC091118; AAH91118.1; -; mRNA.
DR   PIR; A32827; A32827.
DR   RefSeq; NP_037030.1; NM_012898.4.
DR   AlphaFoldDB; P24090; -.
DR   SMR; P24090; -.
DR   BioGRID; 247412; 1.
DR   IntAct; P24090; 2.
DR   STRING; 10116.ENSRNOP00000073898; -.
DR   MEROPS; I25.020; -.
DR   MEROPS; I25.021; -.
DR   GlyCosmos; P24090; 3 sites, No reported glycans.
DR   GlyGen; P24090; 3 sites, 1 N-linked glycan (1 site).
DR   iPTMnet; P24090; -.
DR   PhosphoSitePlus; P24090; -.
DR   SwissPalm; P24090; -.
DR   PaxDb; 10116-ENSRNOP00000055223; -.
DR   Ensembl; ENSRNOT00000058422.5; ENSRNOP00000055223.5; ENSRNOG00000038370.5.
DR   Ensembl; ENSRNOT00055007843; ENSRNOP00055005901; ENSRNOG00055004922.
DR   Ensembl; ENSRNOT00060018994; ENSRNOP00060014819; ENSRNOG00060011231.
DR   Ensembl; ENSRNOT00065005173; ENSRNOP00065003707; ENSRNOG00065003582.
DR   GeneID; 25373; -.
DR   KEGG; rno:25373; -.
DR   UCSC; RGD:2075; rat.
DR   AGR; RGD:2075; -.
DR   CTD; 197; -.
DR   RGD; 2075; Ahsg.
DR   eggNOG; ENOG502RYRI; Eukaryota.
DR   GeneTree; ENSGT00950000182930; -.
DR   InParanoid; P24090; -.
DR   OrthoDB; 5312104at2759; -.
DR   Reactome; R-RNO-114608; Platelet degranulation.
DR   Reactome; R-RNO-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-RNO-6798695; Neutrophil degranulation.
DR   Reactome; R-RNO-8957275; Post-translational protein phosphorylation.
DR   PRO; PR:P24090; -.
DR   Proteomes; UP000002494; Chromosome 11.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; IDA:RGD.
DR   GO; GO:0031012; C:extracellular matrix; IBA:GO_Central.
DR   GO; GO:0005576; C:extracellular region; IBA:GO_Central.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0004869; F:cysteine-type endopeptidase inhibitor activity; IEA:InterPro.
DR   GO; GO:0004866; F:endopeptidase inhibitor activity; IBA:GO_Central.
DR   GO; GO:0019210; F:kinase inhibitor activity; NAS:UniProtKB.
DR   GO; GO:0030294; F:receptor signaling protein tyrosine kinase inhibitor activity; IDA:RGD.
DR   GO; GO:0006953; P:acute-phase response; ISS:UniProtKB.
DR   GO; GO:0031100; P:animal organ regeneration; IEP:RGD.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEP:RGD.
DR   GO; GO:0021987; P:cerebral cortex development; IEP:RGD.
DR   GO; GO:0008584; P:male gonad development; IMP:RGD.
DR   GO; GO:0030502; P:negative regulation of bone mineralization; IMP:RGD.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:RGD.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IDA:RGD.
DR   GO; GO:0001503; P:ossification; ISO:RGD.
DR   GO; GO:0045780; P:positive regulation of bone resorption; IMP:RGD.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; ISS:UniProtKB.
DR   GO; GO:0065003; P:protein-containing complex assembly; IPI:RGD.
DR   GO; GO:0050727; P:regulation of inflammatory response; ISS:UniProtKB.
DR   CDD; cd00042; CY; 2.
DR   Gene3D; 3.10.450.10; -; 2.
DR   InterPro; IPR000010; Cystatin_dom.
DR   InterPro; IPR025760; Cystatin_Fetuin_A.
DR   InterPro; IPR046350; Cystatin_sf.
DR   InterPro; IPR050735; Kininogen_Fetuin_HRG.
DR   InterPro; IPR001363; Prot_inh_fetuin_CS.
DR   PANTHER; PTHR13814:SF6; ALPHA-2-HS-GLYCOPROTEIN; 1.
DR   PANTHER; PTHR13814; FETUIN; 1.
DR   Pfam; PF00031; Cystatin; 1.
DR   SMART; SM00043; CY; 2.
DR   SUPFAM; SSF54403; Cystatin/monellin; 2.
DR   PROSITE; PS51529; CYSTATIN_FETUIN_A; 2.
DR   PROSITE; PS01254; FETUIN_1; 1.
DR   PROSITE; PS01255; FETUIN_2; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Phosphoprotein;
KW   Reference proteome; Repeat; Secreted; Signal.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000269|PubMed:1860865"
FT   CHAIN           19..352
FT                   /note="Alpha-2-HS-glycoprotein"
FT                   /id="PRO_0000008897"
FT   DOMAIN          19..133
FT                   /note="Cystatin fetuin-A-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00861"
FT   DOMAIN          144..250
FT                   /note="Cystatin fetuin-A-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00861"
FT   REGION          256..280
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          319..338
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            143..144
FT                   /note="Cleavage; by trypsin"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         134
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P02765"
FT   MOD_RES         135
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P29699"
FT   MOD_RES         138
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16641100,
FT                   ECO:0007744|PubMed:22673903"
FT   MOD_RES         309
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         313
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         316
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         318
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   CARBOHYD        99
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        156
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        176
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        32..343
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00861"
FT   DISULFID        89..100
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00861"
FT   DISULFID        114..132
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00861"
FT   DISULFID        146..149
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00861"
FT   DISULFID        208..219
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00861"
FT   DISULFID        230..247
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00861"
FT   CONFLICT        21
FT                   /note="Q -> E (in Ref. 6; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        29
FT                   /note="E -> Q (in Ref. 6; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        33..34
FT                   /note="DD -> NN (in Ref. 6; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        46
FT                   /note="D -> H (in Ref. 3; AAA75502)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        76
FT                   /note="E -> Q (in Ref. 3; AAA75502)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        236..237
FT                   /note="HR -> QF (in Ref. 6; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        241..242
FT                   /note="EE -> QQ (in Ref. 6; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        329
FT                   /note="Q -> E (in Ref. 6; AA sequence)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   352 AA;  37982 MW;  43564F60F3C7C90A CRC64;
     MKSLVLLLCF AQLWSCQSAP QGAGLGFREL ACDDPETEHV ALIAVDYLNK HLLQGFRQIL
     NQIDKVKVWS RRPFGEVYEL EIDTLETTCH ALDPTPLANC SVRQQAEHAV EGDCDFHILK
     QDGQFRVLHA QCHSTPDSAE DVRKFCPRCP ILIRFNDTNV VHTVKTALAA FNAQNNGTYF
     KLVEISRAQN VPFPVSTLVE FVIAATDCTG QEVTDPAKCN LLAEKQYGFC KATLIHRLGG
     EEVSVACKLF QTQPQPANAN PAGPAPTVGQ AAPVAPPAGP PESVVVGPVA VPLGLPDHRT
     HHDLRHAFSP VASVESASGE VLHSPKVGQP GDAGAAGPVA PLCPGRVRYF KI
//
